Mark Wood, MD
Internal Medicine · Jonesboro, ARNPI 1760478903
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,817 and has fallen 98.4% since, to $29 in 2025.
Across 163 payments — averaging $12.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$364
- Johnson & Johnson$357
- Pfizer$200
- Sunovion Pharmaceuticals Inc.$176
- Novo Nordisk$137
- AstraZeneca$130
- plus $705 from 16 others
Across 4 payments — averaging $294.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1K
What the payments were for
- Food & beverage$2,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $364 |
| Johnson & Johnson | 28 | $357 |
| Pfizer | 18 | $200 |
| Sunovion Pharmaceuticals Inc. | 28 | $176 |
| Novo Nordisk | 10 | $137 |
| AstraZeneca | 7 | $130 |
| Amgen | 10 | $126 |
| Astellas Pharma US Inc | 10 | $124 |
| Sanofi-aventis U.S. LLC | 9 | $112 |
| Boehringer Ingelheim | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Mylan Specialty L.p. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Cvrx, Inc. | 1 | $29 |
| Merck | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| GSK | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Abbott | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Circassia Inc. | 1 | $12 |
How this compares
$2,068 in reported general payments places this provider in the 80th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 17 | $472 |
| Omeprazole | 12 | $181 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $165 |
| Potassium Chloride | 17 | $155 |
| Furosemide | 24 | $112 |
| Prednisone | 25 | $56 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Jonesboro
- David PyleJonesboro$93K
- John NorwoodJonesboro$21K
- Revel PorterJonesboro$12K
- Ricky TateJonesboro$11K
- Brannon TreeceJonesboro$9K
- Veryl HodgesJonesboro$8K
- Corey DiamondJonesboro$8K
- Veronica EastonJonesboro$5K
- Ben OwensJonesboro$5K
- Stephen PaceJonesboro$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.